REQUEST A DEMO
Total
USD $0.00
Search more companies

Origel Biotechnology 2021 S.R.O. (Czech Republic)

Main Activities: Real Estate | Lessors of Other Real Estate Property
Full name: Origel Biotechnology 2021 S.R.O. Profile Updated: December 09, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Origel Biotechnology 2021 S.R.O. is based in Czech Republic, with the head office in Kladno. The enterprise operates in the Real Estate industry. The enterprise was incorporated on November 14, 2021. 1 - 5 (2024) employees currently work for Origel Biotechnology 2021 S.R.O.. The company’s latest financial report indicates a net sales revenue drop of 23.37% in 2024. During that time, Origel Biotechnology 2021 S.R.O.’s total assets grew by 22.74%.

Headquarters
Kyjevska 2857
Kladno; Stredocesky; Postal Code: 27204

Contact Details: Purchase the Origel Biotechnology 2021 S.R.O. report to view the information.

Basic Information
Total Employees:
Purchase the Origel Biotechnology 2021 S.R.O. report to view the information.
Registered Capital:
Purchase the Origel Biotechnology 2021 S.R.O. report to view the information.
Financial Auditors:
Purchase the Origel Biotechnology 2021 S.R.O. report to view the information.
Incorporation Date:
November 14, 2021
Key Executives
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Origel Biotechnology 2021 S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
-23.37%
Total operating revenue
-23.37%
Operating profit (EBIT)
-86.5%
EBITDA
-86.5%
Net Profit (Loss) for the Period
N/A
Total Assets
22.74%
Total Equity
-21.4%
Operating Profit Margin (ROS)
-8.13%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Quick Ratio
-0.03%
Cash Ratio
0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?